ENTERA BIO LTD
NASDAQ: ENTX (Entera Bio Ltd.)
Last update: 2 hours ago2.95
0.03 (1.03%)
| Previous Close | 2.92 |
| Volume | 143,687 |
| Price / Sales | 1.43 |
| Price / Book | 68.99 |
| 52 Weeks Range |
| Operating Margin (TTM) | -6,102.38% |
| Diluted EPS (TTM) | -0.260 |
| Total Debt/Equity (MRQ) | 1.14% |
| Current Ratio (MRQ) | 13.07 |
| Operating Cash Flow (TTM) | -6.36 M |
| Levered Free Cash Flow (TTM) | -11.17 M |
| Return on Assets (TTM) | -39.60% |
| Return on Equity (TTM) | -71.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Entera Bio Ltd. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 24.42% |
| % Held by Institutions | 22.17% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Knoll Capital Management, Llc | 30 Jun 2026 | 5,881,879 |
| Bvf Inc/Il | 30 Jun 2026 | 2,425,000 |
| Hightower Advisors, Llc | 30 Jun 2026 | 74,573 |
| Signature Estate & Investment Advisors Llc | 30 Jun 2026 | 47,328 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |